Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Depreciation & Amortization - Total: 2019-2025

Historic Depreciation & Amortization - Total for Akebia Therapeutics (AKBA) over the last 5 years, with Sep 2025 value amounting to $318,000.

  • Akebia Therapeutics' Depreciation & Amortization - Total fell 12.40% to $318,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 15.65%. This contributed to the annual value of $1.5 million for FY2024, which is 7.76% down from last year.
  • Akebia Therapeutics' Depreciation & Amortization - Total amounted to $318,000 in Q3 2025, which was up 0.63% from $316,000 recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' Depreciation & Amortization - Total peaked at $408,000 during Q4 2022, and registered a low of $314,000 during Q1 2025.
  • Moreover, its 3-year median value for Depreciation & Amortization - Total was $364,000 (2024), whereas its average is $363,182.
  • Its Depreciation & Amortization - Total has fluctuated over the past 5 years, first rose by 0.76% in 2024, then decreased by 21.00% in 2025.
  • Quarterly analysis of 4 years shows Akebia Therapeutics' Depreciation & Amortization - Total stood at $408,000 in 2022, then decreased by 3.43% to $394,000 in 2023, then fell by 14.97% to $335,000 in 2024, then decreased by 12.40% to $318,000 in 2025.
  • Its Depreciation & Amortization - Total stands at $318,000 for Q3 2025, versus $316,000 for Q2 2025 and $314,000 for Q1 2025.